MA40218A - Procédés pour le traitement d'infections par le virus de l'hépatite b et le virus de l'hépatite d - Google Patents

Procédés pour le traitement d'infections par le virus de l'hépatite b et le virus de l'hépatite d

Info

Publication number
MA40218A
MA40218A MA040218A MA40218A MA40218A MA 40218 A MA40218 A MA 40218A MA 040218 A MA040218 A MA 040218A MA 40218 A MA40218 A MA 40218A MA 40218 A MA40218 A MA 40218A
Authority
MA
Morocco
Prior art keywords
hepatitis
treatment
virus
methods
virus infections
Prior art date
Application number
MA040218A
Other languages
English (en)
Other versions
MA40218B1 (fr
Inventor
Andrew Vaillant
Original Assignee
Replicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Replicor Inc filed Critical Replicor Inc
Priority claimed from PCT/CA2015/050626 external-priority patent/WO2016004525A1/fr
Publication of MA40218A publication Critical patent/MA40218A/fr
Publication of MA40218B1 publication Critical patent/MA40218B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un procédé pour traiter une infection par le virus de l'hépatite b ou une co-infection par le virus de l'hépatite b et par le virus de l'hépatite d, ce procédé consistant à administrer à un sujet ayant besoin d'un tel traitement un premier agent pharmaceutiquement acceptable qui comprend au moins un polymère d'acide nucléique phosphorothioaté et un second agent pharmaceutiquement acceptable qui comprend au moins un analogue de nucléoside/nucléotide inhibiteur de la polymérase du vhb.
MA40218A 2014-07-10 2015-07-07 Polymères d'acides nucléiques phosphorotiotés chélatés pour une utilisation en combinaison avec un inhibiteur de la polymerase du hbv dans le traitement d'infections par le virus de l'hépatite b et le virus de l'hépatite d MA40218B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462022846P 2014-07-10 2014-07-10
PCT/CA2015/050626 WO2016004525A1 (fr) 2014-07-10 2015-07-07 Procédés pour le traitement d'infections par le virus de l'hépatite b et le virus de l'hépatite d

Publications (2)

Publication Number Publication Date
MA40218A true MA40218A (fr) 2017-05-17
MA40218B1 MA40218B1 (fr) 2023-11-30

Family

ID=58699753

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40218A MA40218B1 (fr) 2014-07-10 2015-07-07 Polymères d'acides nucléiques phosphorotiotés chélatés pour une utilisation en combinaison avec un inhibiteur de la polymerase du hbv dans le traitement d'infections par le virus de l'hépatite b et le virus de l'hépatite d

Country Status (2)

Country Link
AR (1) AR101126A1 (fr)
MA (1) MA40218B1 (fr)

Also Published As

Publication number Publication date
MA40218B1 (fr) 2023-11-30
AR101126A1 (es) 2016-11-23

Similar Documents

Publication Publication Date Title
MY178087A (en) Methods for the treatment of hepatitis b and hepatitis d virus infections
PH12017500614A1 (en) Compositions and methods for silencing hepatitis b virus gene expression
HK1248278A1 (zh) 用於使乙型肝炎病毒基因表达沉默的组合物及方法
ZA201901061B (en) 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
SG11201801809VA (en) Method for modifying genome sequence that specifically converts nucleobase of targeted dna sequence, and molecular complex used in said method
JOP20170130A1 (ar) مركبات لمعالجة عدوى فيروس التهاب الكبد الوبائي b
WO2016183366A3 (fr) Compositions et méthodes permettant l'extinction de l'expression de l'arn du virus de l'hépatite d
MX2016002586A (es) Métodos y composiciones para el tratamiento guiado por rna de infección por hiv.
EP4659765A3 (fr) Délétion d'exon du gène codant la dystrophine au moyen de nucléases génétiquement modifiées
WO2017027350A3 (fr) Thérapie par interférence arn pour l'infection par le virus de l'hépatite b
MX373703B (es) Derivados de azepano y metodos para tratar infecciones por hepatitis b.
WO2015042308A3 (fr) Inhibiteurs du vih à base d'arn
HK1251010A1 (zh) 用於治疗乙型肝炎病毒(hbv)感染的试剂及用途
PH12018502320A1 (en) Reagents for treatment of hepatitis b virus (hbv) infection and use thereof
MA40218A (fr) Procédés pour le traitement d'infections par le virus de l'hépatite b et le virus de l'hépatite d
NZ727583B2 (en) Methods for the treatment of hepatitis b and hepatitis d virus infections
IL286484B (en) Reagents for treatment of hepatitis b virus (hbv) infection and use thereof
HK40008711A (en) 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
AU2015901617A0 (en) Reagents for treatment of hepatitis B virus (HBV) infection and use thereof
JO3769B1 (ar) علاج RNAi لعدوى فيروس التهاب الكبد B